Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely Acquires 175,000 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely acquired 175,000 shares of the company’s stock in a transaction dated Friday, March 14th. The stock was acquired at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the completion of the purchase, the chief executive officer now directly owns 712,500 shares of the company’s stock, valued at $434,625. This trade represents a 32.56 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lyell Immunopharma Stock Down 6.5 %

LYEL stock opened at $0.48 on Wednesday. Lyell Immunopharma, Inc. has a twelve month low of $0.48 and a twelve month high of $3.15. The company has a market cap of $142.80 million, a PE ratio of -0.61 and a beta of -0.41. The business’s 50-day simple moving average is $0.62 and its 200 day simple moving average is $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, equities research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in LYEL. Centiva Capital LP acquired a new position in shares of Lyell Immunopharma in the 3rd quarter worth approximately $31,000. Graham Capital Management L.P. acquired a new position in shares of Lyell Immunopharma in the 4th quarter worth approximately $33,000. RPO LLC bought a new position in Lyell Immunopharma in the 4th quarter worth approximately $42,000. Intech Investment Management LLC bought a new position in Lyell Immunopharma in the 3rd quarter worth approximately $52,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Lyell Immunopharma in the 3rd quarter worth approximately $52,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.